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154 Poster Session-IIsubcutaneous group.We conclude that subcutaneous administration
of alemtuzumab shows similar outcomes as intravenous administra-
tion in the reduced intensity preparatory regime for non-malignant
diseases with less toxicity to the patient.438
USE OF A CALCIUM/PHOSPHATE ORAL RINSE (CAPHOSOLR) TO LESSEN
THE MUCOSITIS FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION
Bechtel, T.P.1, Devine, S.2 1Arthur G James Cancer Hospital and Richard
J Solove Research Institute at the Ohio State University Medical Center,
Columbus, OH; 2Arthur G James Cancer Hospital and Richard J Solove
Research Institute at the Ohio State UniversityMedical Center, Columbus,
OH
The high-dose chemotherapy/radiation therapy employed in the
conditioning regimens prior to hematopoietic stem cell transplanta-
tion have a considerable negative effect on the oral epithelium. De-
pending on the agents and doses administered, oral mucositis can
range from mild to life threatening. The consequences of this
mucositis, depending on its degree, can impact a patients ability to
maintain oral hydration, nutrition and intake of medications. Addi-
tionally, the potential for local and systemic infections increases dra-
matically with the loss of the natural mucosal barrier. Many
interventions have been tried over the years to lessen the degree of
mucositis and all have met with mixed, inconsistent results. The re-
cent introduction of a new agent, CaphosolR, has added to the list of
potential treatments. One conditioning protocol that has consis-
tently produced varying degrees of mucositis in our patients is the
BEAM regimen. It consists of carmustine, etoposide, cytarabine
and melphalan given intravenously over a 6 day period and is widely
used in the non-Hodgkins lymphoma population. Previous attempts
to modify the mucositis have been met with marginal success so it
was decided to trial CaphosolR in this setting. CaphosolR was pre-
pared according to the manufacturers instructions and administered
4 times daily to 9 patients receiving the BEAM regimen. This group
was compared to 13 patients that received BEAM in the previous 6
months who did not get CaphosolR. Some degree of mucositis was
seen in all the patients which required narcotic analgesic interven-
tion. Themost severe cases required the use of patient controlled an-
algesia (PCA) with either morphine or hydromorphone. We found
that four (4) patients in each group needed PCA however the Capho-
solR group needed a mean of only 4.25 days of PCA therapy vs 5.5
days in the other group and the overall patient pain rating was less
in the CaphosolR population. We also found that the length of
stay after transplantation (LOS) was 1.5 days less in the CaphosolR
group (14.5 vs 15.9 days) while the mean number of days on Capho-
solR was 10.2. It was felt that the treatment had a positive effect on
patient outcome and quality of life and it is now used in all patients
receiving BEAM therapy. We continue to evaluate it in this group
along with other transplant populations, non-transplant chemother-
apy patients and those receiving radiotherapy for head/neck cancer.439
ATTENUATED KERATINOCYTE GROWTH FACTOR AND ETOPOSIDE
BASED CONDITIONING FOR ALLOGENEIC TRANSPLANT
Booth, D.L. Royal Melbourne Hospital, Melbourne, Victoria, Australia
Objective:Assess the impact of keratinocyte growth factor (KGF)
administered prior to conditioning only, on oral mucositis in alloge-
neic transplant recipients receiving etoposide based conditioning.
Method: All patients scheduled for HSCT with TBI/ Etoposide
or Bu/Cy/Etoposide from June 2006 to August 2008 were offered
KGF at 60 mcg/kg on 3 consecutive days finishing 24 hours prior
to conditioning. Work previously done in our institution showed
KGF was not beneficial in allogeneic patients receiving myeloabla-
tive conditioning regimens. This result was attributed to scheduling
of post conditioning KGF and short course methotrexate despite
omission of day11 KGF to avoid coadministration within 24 hours.
Therefore, in this cohort of patients post conditioning KGF doses
were omitted completely. WHO oral mucositis score, duration,
TPN and analgesia usage were recorded prospectively.
Results: Twelve patients (8 allogeneic, 4 MUDs, 7 B-ALL, 2
Ph1ve ALL, 2 T-ALL, 1 biphenotypic leukaemia) consented toKGF. Conditioning was TBI/etoposide in 10 patients TBI/thymo-
globulin/etoposide in 1 patient and Bu/Cy/etoposide in 1 patient
with CSA and MTX on days 1, 3, 6 and 11 as GVHD prophylaxis.
Grade 3 to 4 mucositis was experienced by 8/12 patients (67%) com-
pared to 36/38 (95%) of TBI etoposide patients prior to June 2006
(P 5 0.024). Mean duration of TPN was 13.5 days compared to
18 days and mean duration of opiate analgesia was 11.5 days
compared 14.5 days for KGF cohort and the historical cohort
respectively.
Conclusions: Attenuated KGF is effective for amelioration of
oral mucositis associated with etoposide containing conditioning
in allogeneic transplants.440
A RAPID NANOPARTICLE IMMUNOASSAY TO QUANTITATE BUSULFAN IN
PLASMA
Salamone, S.J.1, Benfield, C.N.1, Courtney, J.B.1, Harney, R.L.1,
Kozo, D.R.1, Li, Y.1, Lundell, G.D.1, Shaw, L.M.2, Gardiner, J.A.M.2
1Saladax Biomedical Inc, Bethlehem, PA; 2University of Pennsylvania
Medical Center, Philadelphia, PA
Background: Busulfan (BU), a bifunctional alkylating agent, is
the most widely used chemotherapeutic agent as a component of
high-dose conditioning regimens for hematopoietic stem cell trans-
plantation (HSCT). Studies have shown that maintaining a targeted
exposure [expressed as area under the time-curve (AUC)] throughout
the complete regimen is essential for successful engraftment,
reduced risk of graft vs. host disease or venoocclusive disease. For
optimal therapeutic drug management (TDM), an assay that can
deliver rapid high quality results would be desirable.
Methods: Monoclonal antibodies bound to nanoparticles were
used to develop an immunoassay for the Roche c111 chemistry
analyzer. The assay was monitored at 629 nm and quantitated with
a stabilized calibrator of busulfan. Assay precision, linearity, calibra-
tion stability and limit of detection (LoD) were determined. Clinical
samples were analyzed and correlated with GC-MS.
Results:With six calibrators from0–2,000 ng/mL, a stabilized bu-
sulfan derivative, and auto-dilution, plasma samples with concentra-
tions up to 10,000 ng/mL could be determined. Time-to-first-result
was 12 min and 25 samples/h could be measured from a stored stan-
dard curve. Imprecision across the range of assay was\7% and the
assaywas linear upondilutionover the entire range.Cross-reactivities
for sulfolane, tetrathiophene and 3-hydroxsulfolane were\1%. The
LoDwas 50 ng/mLwith a functional sensitivity of 100 ng/mL. Assay
results of clinical samples (237 to 1,711ng/mL) correlated well with
GC-MS results: (R. 0.98, slope 1.05, intercept5 39 ng/mL).
Conclusions: This immunoassay is suitable for determining bu-
sulfan concentrations in plasma. It offers advantages of turn-around
time, small sample size, no sample pre-treatment and a stable calibra-
tor that can be stored at room temperature. Automation and rapid
turn-around time with a small benchtop analyzer enable efficient
routine monitoring of busulfan concentrations in clinical practice
which can lead to better patient care.441
PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL
BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA
(AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
Hutcherson, D.A.1, Surati, M.1, Sanvidge, K.1, Harvey, D.2, Al-
Baldawi, R.N.3, Langston, A.2, Flowers, C.2, Lonial, S.2, Kaufman, J.2,
Lechowicz, M.J.2, Waller, E.2 1Emory Healthcare, Atlanta, GA; 2Emory
University, Atlanta, GA; 3Mercer University, Atlanta, GA
Background: Busulfan (Bu) and cyclophosphamide are widely
used in conditioning regimens before hematopoietic cell transplan-
tation. Increased relapse rates and graft rejection have previously
been reported with low Bu area-under-the-curve (AUC) micromol*
min/L, and sinusoidal obstruction syndrome is associated with high
AUCs.This has lead to strategies to adjust Bu dosing to achieve a tar-
get AUC. Previous studies have suggested that a 0.8 mg/kg dose of
IV Bu would achieve an AUC similar to that of 1 mg/kg of oral
Bu. PK monitoring of IV Bu at our institution demonstrated that
Poster Session-II 1550.8 mg/kg often failed to achieve our target AUC of 1150–1350. Fif-
teen AML/MDS patients receiving 0.8 mg/kg had a mean AUC of
1059 (822–1653), with 12 AUCs\1150. Subsequently, our routine
starting dose of IV Bu was changed to 0.9 mg/kg.
Methods: We performed a retrospective review of AML and
MDS patients from an IRB approvedHIPAA compliant database es-
tablished for the collection and analysis of Bu PK. Data from two
groups of Bu patients treated between 1998 and 2008 were analyzed.
Fifty-eight patients were treated with oral Bu (1 mg/kg) and fifty-
eight patients were treated with IV Bu (0.9 mg/kg). Bu AUCwas de-
termined for the first dose and adjustments weremade on subsequent
doses to target an AUC of 1150–1350.
Results: Median age for IV and oral Bu patients was 42 (18–68)
and 47 (23–67), respectively (p 5 0.0049). The mean terminal half-
life (T1⁄2 ) was 186 minutes (131–253) for IV Bu and 181 minutes
(110–305) for oral Bu (p 5 NS). Mean AUCs were 1115 (777–
1569) for IV Bu patients and 1260 (654–2019) for oral Bu (p 5
0.0094). Seventeen (29.3%) patients in each group achieved AUCs
within our target of 1150–1350. Thirty-four (58.6%) IV Bu patients
had AUCs\1150 compared to twenty (34.5%) oral Bu patients (p5
0.0092). Eight (13.8%) IV Bu patients had AUCs .1350 compared
to twenty-one (36.2%) oral Bu patients (p 5 0.0053).
Conclusions:While first dose PK analysis showed similar T1⁄2 for
IV and oral Bu, the AUCs achieved with 0.9 mg/kg IV Bu are lower
than with 1mg/kg oral Bu dosing. First-dose AUC from recipients of
IV Bu had a lower variance than AUC from recipients of oral Bu.
Despite changing our starting IV Bu dosing from 0.8 mg/kg to
0.9 mg/kg, the majority of patients still require therapeutic drug
monitoring with dose adjustments to obtain our desired target
AUC of 1150–1350.442
ARETROSPECTIVE ANALYSIS OF RISK FACTORS THAT INFLUENCE INTRA-
VENOUS BUSULFAN KINETICS IN ADULT PATIENTS
McBride, A.1, Fancher, K.1, Perkins, J.1, Milone, M.2, Shaw, L.2,
Conwell, M.1 1H. Lee Moffitt Cancer Center & Research Institute,
Tampa, FL; 2Hospital of the University of Pennsylvania, Philadelphia, PA
Busulfan (Bu) is a bifunctional alkylating agent that is a common
component of conditioning regimens prior to hematopoetic stem
cell transplantation (HSCT). Bu pharmacokinetics, either with area
under the curve (AUC) or average concentration at steady state
(Css), can be utilized to evaluate efficacy and prevent adverse effects
such as hepatic veno-occlusive disease (VOD). Pharmacokinetic
models that predict Bu levels were historically performed with q 6
hour oral dosing in the pediatric population and used a limited linear
regressionmodel. Since the advent of intravenous (IV)Bu, a consistent
pharmacokinetic modeling system based on specific patient parame-
ters has not emerged. Likewise, current Bu pharmacokinetics models
may not be accurate in adult patients or with once-daily dosing sch-
edules. We will report a retrospective study of approximately 300
patients and present a predictive pharmacokineticmodel for appropri-
ate AUC with once-daily IV Bu in adult patients. Our model will be
based on first dose kinetic analyses. We will also evaluate currently
published risk factors that may influence IV Bu kinetic parameters us-
ing univariate,multivariate and stepwiseCox regression analyses. Age,
race, gender, disease state, disease status at time of transplantation,
number of previous chemotherapy regimens, renal and hepatic func-
tion at time of transplant and graft source will be evaluated. Long-
term outcomes to be examined include overall mortality, probability
of survival, development of acute and chronic graft versus host disease
(GVHD), development of VODand days until neutrophil and platelet
engraftment. Statistical model design and specific data results will be
presented at the 2009 ASBMT Annual Conference.443
AN ANALYSIS OF TOXICITIES AND TIME TO ENGRAFTMENT ASSOCIATED
WITH THREE DISTINCT MELPHALAN TREATMENT SCHEMAS IN PA-
TIENTS WITH MULTIPLE MYELOMA RECEIVING AUTOLOGOUS HEMATO-
POETIC STEM CELL TRANSPLANTATION
Maewal, I.1, Kurtzweil, A.J.1, Shapiro, J.F.2, Westmoreland, M.D.1,
Bassett RL Jr., Jr.,3, Giralt, S.A.4 1MD Anderson Cancer Center, Hous-
ton, TX; 2H. Lee Moffitt Cancer Center and Research Institute, Tampa,FL; 3MDAnderson Cancer Center, Houston, TX; 4MDAnderson Cancer
Center, Houston, TX
At MD Anderson Cancer Center, the standard-of-care prepara-
tory regimen in patients with multiple myeloma receiving an autol-
ogous stem cell transplant is melphalan 200 mg/m2 given over two
days with one day of rest prior to transplant. The primary objective
of this study is to determine if differences exist in the severity of tox-
icities in patients with multiple myeloma who receive melphalan as
a preparatory regimen in three distinct treatment schema. The sec-
ondary objective of this study is to ascertain the differences in time
to engraftment in this population. Toxicities, defined as nausea,
vomiting, diarrhea, renal and hepatic dysfunction, were graded using
the NCI-CTCAE. Pain secondary to mucositis was recorded based
on the use of patient-controlled analgesia. We performed a retro-
spective review in patients who received one of the following prepa-
ratory regimens: arm 1) melphalan 200 mg/m2 over days -3 and -2,
arm 2) melphalan 200 mg/m2 over day -2, or arm 3) melphalan
200 mg/m2 over days -2 and -1. This review included patients over
the age of 18 in first remission or with primary refractory disease
who received autologous transplantation within 12 months of diag-
nosis. Patients who received prior transplantation were excluded
from this review. 164 patients were identified from the institutional
database for data collection and 100 patients were selected at random
for this interim analysis. The majority of patients identified were
male,\65, ISS stage of I-II, and had an ECOG performance status
of 0–1. With respect to the primary endpoint, no statistically signif-
icant differences were observed in the severity of toxicity when com-
paring the treatment schemas (nausea: p5 0.55; vomiting: p5 0.46;
diarrhea: 0.52, Kruskal-Wallis test and PCA use secondary to mu-
cositis: p 5 0.82, Fisher’s exact test). With regard to time to en-
graftment, the actual difference between the arms was
approximately 1 day, yet the comparison between the three groups
was statistically significant (p\0.001, log-rank test). We concluded
that differences between the three treatment schemas in the severity
of toxicities were neither statistically nor clinically significant; the
differences in time to engraftment were not clinically significant.
Based on the interim analysis, this review demonstrates the poten-
tial for melphalan to be administered in any one of three distinct
treatment schemas without resulting in adverse effects on toxicity
and time to engraftment.
Results
Arm 1 Arm 2 Arm 3Grade 3-4 Toxicity(N544) (N537) (N519)n (%) n (%) n (%)Nausea 2 (4.5%) 1 (2.7%) 0
Vomiting 2 (4.5%) 0 0
Diarrhea 0 2 (5.4%) 0
Serum creatinine 0 0 0
Total bilirubin 0 1 (2.7%) 0
Pain 5 (11.4%) 4 (10.8%) 1 (5.3%)
Time to engraftment (median) 10 days 11 days 10 days444
SUCESSFUL OUTCOME AFTER ACCIDENTAL HIGH DOSE CYTARABINE (HI-
DAC) INFUSION SEVEN DAYS POST UNRELATED DONOR (UD) CORD
BLOOD (CB) STEM CELL TRANSPLATION (SCT)
Stelts, S., Nath, R. Methodist University Hospital/University of Tennessee
Cancer Institute, Memphis, TN
Introduction:The complex regimens of allogenic SCT increase
the risk of medication errors. We report an accidental HIDAC infu-
sion post UD-CBSCT and the patient outcome.
Case Report: A 24 year old heavily pretreated female with history
of relapsed philadelphia (Ph) positive acute lymphoblastic leukemia
received a 4/6 matched UD-CBST. The patient received a prepara-
tory regimen of fludarabine 30 mg/m2 on days -7 to -3, melphalan
70 mg/m2 on day -3 and -2, and antithymocyte immunoglobulin
10mg/kg on days -4 and -2. Graft versus host disease (gvhd) prophy-
laxis consisted of tacrolimus (level 5 -15 ng/ml) and mycophenolate
